Nuclera announces the appointment of Jonathan Milner as Chairman of the Board
January 8, 2024
Cambridge, UK – 8th January 2024: Nuclera, the pioneer in bringing rapid protein prototyping to the benchtop, is delighted to announce the appointment of Jonathan Milner as the Non-executive Chairman of the Board of Directors.
Dr Milner joins Nuclera’s board with a wealth of experience as the founder and former CEO of Abcam – the e-commerce company specializing in antibodies. The firm expanded to become one of Britain’s most successful biotechnology companies and it was recently acquired by Danaher, the US conglomerate, for $5.7billion.
Dr Milner, 58, is also an experienced life science investor, and is passionate about the UK’s life sciences industry making him the ideal person to join the Nuclera team. Jonathan participated in Nuclera’s Series B financing round in 2021.
Working directly with co-founders Dr Michael Chen, Dr Jiahao Huang and Dr Gordon McInroy, Jonathan joins Nuclera at an exciting time for the firm as it has recently announced partnerships with Google Cloud’s AlphaFold2 and AI partner DeepMirror. These collaborations will further extend the capabilities of Nuclera’s eProtein DiscoveryTM, enabling it to accelerate the start of the drug discovery process by more than 20x, in turn saving companies millions of dollars every year.
Michael Chen, CEO and co-founder of Nuclera, said: “We are thrilled to have Jonathan join the Nuclera team. He is a titan in the life sciences industry and we are delighted to have him on board as we grow from strength to strength. I look forward to working with him and sharing our ideas on how Nuclera’s technology can be best used to accelerate breakthrough improvements in human health.”
Jonathan Milner, Non-Executive Chairman of the Board of Directors at Nuclera and Founder of Abcam, said: “Nuclera is pioneering a solution which has been long sought after. The ability to screen multiple protein expression and purification profiles and deliver reliable proteins in-hand in less than 48 hours will revolutionize laboratory workflows and make a demonstrable impact in terms of time to publish in academia and drug discovery timelines. I am delighted to join the Nuclera team as they bring the eProtein Discovery System to the market.”
